Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are studying adults aged 45 to 80 who have high levels of Lipoproteina, known as Lpa, a protein linked to higher risk of heart disease. The trial aims to compare the effects of lepodisiran, a drug given by injection, to a placebo on the amount and type of plaque in the hearts vessels using advanced imaging called Coronary Computed Tomography Angiography CCTA. This study is a Phase 3 randomized, double-blind trial focusing on treatment for cardiovascular disease or risk for a first cardiovascular event. Participants will receive either lepodisiran or a placebo by subcutaneous injection. The study will follow them for about 120 weeks, including assessments at baseline and at Week 104 to measure changes in noncalcified plaque volume in the coronary arteries. Secondary measures include changes in fat attenuation index, Lpa levels, participant feedback on the injection experience, and drug pharmacokinetics. During the study, participants will undergo imaging scans, blood tests, and questionnaires at scheduled times to track the effects of the drug compared to placebo. Researchers will monitor the plaque in coronary arteries and Lpa levels to understand how lepodisiran may impact cardiovascular health. Safety and participant experience with the treatment will also be assessed throughout the trial duration.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are evaluating chemotherapy dosing strategies in older patients aged 70 years and above who have metastatic colorectal cancer and are eligible for first-line palliative chemotherapy. This phase III randomized controlled trial aims to compare upfront dose-reduced chemotherapy with standard full-dose chemotherapy, focusing on progression-free survival PFS. Patients are assessed using the Geriatric 8 G8 questionnaire to determine their risk of chemotherapy toxicity, which guides treatment assignment. The study seeks to balance treatment effectiveness with minimizing toxicity, hospital admissions, and maintaining quality of life QoL and physical functioning. Participants classified as low risk for toxicity G8 score 15 or higher are randomized to receive either doublet chemotherapy a fluoropyrimidine combined with oxaliplatin at full dose or with a 25% dose reduction upfront. Those at high risk G8 score 14 or lower or judged high risk by their oncologist receive fluoropyrimidine monotherapy either at full dose or with a 25% dose reduction. The study also allows the addition of targeted treatments like bevacizumab or EGFR inhibitors. Dose adjustments are made for patients with moderate kidney impairment. Chemotherapy is given orally or intravenously on schedules varying between every two and three weeks, depending on the regimen. Participants will be closely monitored throughout treatment, with assessments including radiological or clinical evaluations for disease progression, quality of life and physical functioning questionnaires at 1, 3, 6, and 12 months, and tracking of chemotherapy toxicity, overall survival, treatment cycles, dose changes, hospital admissions, and cumulative drug dosage. Safety and cost-effectiveness will also be evaluated over an average study duration of eight months and up to one year for some outcomes. The study plans to include 587 patients and will continue until December 2028.
Actively Recruiting
Acute urinary retention AUR is a sudden and painful condition where a man cannot urinate, often caused by an enlarged prostate known as benign prostatic hyperplasia BPH. Treatment usually starts with inserting a catheter to empty the bladder and taking medication called alpha-blockers. This study compares two different lengths of catheter use before trying to urinate again, known as the Trial Without Catheter TWOC, to find out if a shorter catheter period is as effective and safe as a longer one. The trial includes 478 men with AUR who all receive a catheter and start or continue alpha-blocker treatment. Participants are randomly assigned to have the catheter removed either after three days or after fourteen days. The study examines if the shorter catheter duration works as well as the longer one in allowing normal urination without needing catheter replacement. It also looks at complications, patient comfort, quality of life, and healthcare costs. During the study, researchers will monitor how many men need re-catheterization after their TWOC, assess patient-reported symptoms and quality of life at multiple time points up to six months, and track complications and healthcare expenses up to 18 months after catheter insertion. The goal is to identify the best timing for catheter removal to reduce discomfort and complications and improve care. Participation lasts through these assessments and follow-ups as scheduled by the research team.
Actively Recruiting
Researchers are evaluating the effects of two types of burst spinal cord stimulation SCS on pain relief and emotional aspects of pain in patients with Persistent Spinal Pain Syndrome Type 2 PSPS Type 2, also known as Failed Back Surgery Syndrome. The trial compares active recharge burst SCS versus passive recharge burst SCS, as no prior clinical studies have directly compared these two waveform methods. This randomized clinical trial aims to improve understanding of how different burst waveforms influence pain experience. The trial enrolls 96 patients across six Dutch hospitals who are randomly assigned to receive either active recharge or passive recharge burst SCS. After a successful trial period, patients will be permanently implanted with the assigned device. Active recharge burst uses negative pulses to directly compensate for charge differences, while passive recharge burst passively compensates for charge differences. Treatments are assessed over 12 months following implantation. Participants will complete various assessments including the Pain Catastrophizing Scale PCS at 6 months as the primary outcome. Secondary measures include pain ratings, patient vigilance, anxiety and depression scales, quality of life, disability index, patient global impression of change, and painDETECT questionnaires at baseline, after trial, and at 1, 3, 6, and 12 months post-implantation. The study monitors device usage and collects patient-reported outcomes to evaluate differences in pain relief and emotional response.
Actively Recruiting
Researchers are investigating whether taking breaks from the standard combination therapy of daratumumab, lenalidomide, and dexamethasone Dara-Rd for newly diagnosed multiple myeloma patients affects survival and quality of life. This study aims to compare continuous treatment versus planned treatment-free intervals to see if stopping therapy temporarily may reduce side effects, allow recovery from toxicity, and improve overall well-being while controlling the disease. Participants who have completed 12 cycles of Dara-Rd with at least a partial response and no signs of disease progression will be randomly assigned to one of two groups. One group will continue Dara-Rd therapy without interruption until disease progression, while the other group will stop treatment temporarily and restart it at biochemical progression, continuing until disease progression. The trial is open-label and will follow patients for several years to assess outcomes. Throughout the study, researchers will monitor participants event-free survival and progression-free survival for up to about 57 and 69 months, respectively. Additional assessments include side effect burden, patient-reported quality of life, treatment costs, treatment-free interval length, response times, and survival after second-line therapy. Regular evaluations will help determine how treatment interruption affects toxicity, dose intensity, and overall treatment outcomes over the long term.
Actively Recruiting
This research aims to evaluate individualized thrombosis prevention after total hip or knee replacement surgery. Despite standard blood thinner treatment given to all patients to prevent venous thromboembolism VTE, some still develop clots while others experience bleeding. The study investigates whether customizing the type and duration of blood thinner treatment based on each patients medical history can reduce both clotting and bleeding risks compared to the standard uniform approach. Participants are grouped by their predicted VTE risk using the TRiPplasty score into low, intermediate, or high risk. Low-risk patients are randomized to receive either standard prophylaxis or a shortened treatment only during hospital stay. High-risk patients are randomized to receive standard treatment or a higher dose for six weeks. Intermediate-risk patients are observed without treatment changes. Blood thinners used include types of LMWH or DOACs given according to local standards, with dosing timing specified after surgery. Participants complete four questionnaires one before surgery and follow-ups at 2 weeks, 6 weeks, and 3 months post-surgery to report any VTE or bleeding events. An additional questionnaire is sent one year after surgery if certain complications occurred, assessing quality of life and joint function. No extra hospital visits are required. The main outcomes measured are symptomatic VTE and major bleeding within 90 days post-surgery, along with other health and quality of life measures up to one year.
Actively Recruiting
Researchers are evaluating whether low-dose colchicine, an anti-inflammatory drug, can reduce the risk of serious vascular events in patients with symptomatic peripheral artery disease PAD. This study is a randomized, double-blind, multicenter trial involving 6,150 participants, aiming to prevent events such as heart attack, stroke, cardiovascular death, severe limb ischemia, and major vascular amputation. The primary outcome measured is a combination of major adverse cardiovascular and limb events MACE and MALE. Participants are randomly assigned to receive either colchicine 0.5 mg once daily or a placebo that looks identical. The trial includes an active run-in period and will continue over a period of 3 to 5 years, during which patients take their assigned tablets daily. Both the active drug and placebo are stored securely and administered under blinded conditions so neither patients nor investigators know which treatment is given. Throughout the study, participants will be regularly monitored for cardiovascular events and limb health. Evaluations include tracking occurrences of heart attacks, strokes, hospitalization, vascular interventions, amputations, and mortality. Quality of life and physical activity are also assessed using specific questionnaires. Safety monitoring and follow-up will continue for the duration of the trial, which may last up to 5 years for each participant.
1-10 of 18
1